These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 35281041)

  • 1. Elevated SNRPA1, as a Promising Predictor Reflecting Severe Clinical Outcome
    Jiang A; Meng J; Gong W; Zhang Z; Gan X; Wang J; Wu Z; Liu B; Qu L; Wang L
    Front Immunol; 2022; 13():842069. PubMed ID: 35281041
    [TBL] [Abstract][Full Text] [Related]  

  • 2. POLD1 as a Prognostic Biomarker Correlated with Cell Proliferation and Immune Infiltration in Clear Cell Renal Cell Carcinoma.
    Tian J; Cheng C; Gao J; Fu G; Xu Z; Chen X; Wu Y; Jin B
    Int J Mol Sci; 2023 Apr; 24(7):. PubMed ID: 37047824
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DDX39 as a predictor of clinical prognosis and immune checkpoint therapy efficacy in patients with clear cell renal cell carcinoma.
    Bao Y; Jiang A; Dong K; Gan X; Gong W; Wu Z; Liu B; Bao Y; Wang J; Wang L
    Int J Biol Sci; 2021; 17(12):3158-3172. PubMed ID: 34421357
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CCNA2 as an Immunological Biomarker Encompassing Tumor Microenvironment and Therapeutic Response in Multiple Cancer Types.
    Jiang A; Zhou Y; Gong W; Pan X; Gan X; Wu Z; Liu B; Qu L; Wang L
    Oxid Med Cell Longev; 2022; 2022():5910575. PubMed ID: 35401923
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low DAPK1 expression correlates with poor prognosis and sunitinib resistance in clear cell renal cell carcinoma.
    Song Z; Li Z; Han W; Zhu C; Lou N; Li X; Luo G; Peng S; Li G; Zhao Y; Guo Y
    Aging (Albany NY); 2020 Nov; 13(2):1842-1858. PubMed ID: 33201837
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Key sunitinib-related biomarkers for renal cell carcinoma.
    Peng Y; Dong S; Song Y; Hou D; Wang L; Li B; Wang H
    Cancer Med; 2021 Oct; 10(19):6917-6930. PubMed ID: 34402193
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dyskerin and telomerase RNA component are sex-differentially associated with outcomes and Sunitinib response in patients with clear cell renal cell carcinoma.
    Yuan H; Qin X; Yang Q; Liu L; Fang Z; Fan Y; Xu D
    Biol Sex Differ; 2023 Jul; 14(1):46. PubMed ID: 37434223
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic value of JAK3 promoter methylation and mRNA expression in clear cell renal cell carcinoma.
    Long Q; Huang C; Huang J; Meng Q; Cheng Y; Li Y; He L; Chen M; Zhang C; Wang X; Zhu W; Peng J; Shi D; Zheng F; Dong P; Deng W
    J Adv Res; 2022 Sep; 40():153-166. PubMed ID: 36100323
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Integrated analysis of immune-related gene subtype and immune index for immunotherapy in clear cell renal cell carcinoma.
    Bai D; Chen S; Feng H; Yin A; Lu J; Ma Y; Sugiyama H
    Pathol Res Pract; 2021 Sep; 225():153557. PubMed ID: 34329838
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk signature identification and NPRL2 affects sunitinib sensitivity in clear cell renal cell carcinoma.
    Du X; Zhao Z; Zhao X; Wang H; Jiang L; Tang W
    Biochem Biophys Res Commun; 2023 Jun; 663():122-131. PubMed ID: 37121122
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Upregulation of serine metabolism enzyme PSAT1 predicts poor prognosis and promotes proliferation, metastasis and drug resistance of clear cell renal cell carcinoma.
    Ye J; Huang X; Tian S; Wang J; Wang H; Feng H; Zhao X; Cao S; Xuan Y; Li X; Ma X; Huang Y; Zhang X
    Exp Cell Res; 2024 Apr; 437(1):113977. PubMed ID: 38373588
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An immune-related lncRNA risk coefficient model to predict the outcomes in clear cell renal cell carcinoma.
    Tang C; Qu G; Xu Y; Yang G; Wang J; Xiang M
    Aging (Albany NY); 2021 Dec; 13(24):26046-26062. PubMed ID: 34954690
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of candidate biomarker
    Lv Q; Xiao W; Xiong Z; Shi J; Miao D; Meng X; Yuan H; Yang H; Zhang X
    Front Biosci (Landmark Ed); 2021 Nov; 26(11):1176-1190. PubMed ID: 34856762
    [No Abstract]   [Full Text] [Related]  

  • 14. High expression levels of DEF6 predicts a poor prognosis for patients with clear cell renal cell carcinoma.
    Zhu ZP; Lin LR; Lv TD; Xu CR; Cai TY; Lin J
    Oncol Rep; 2020 Nov; 44(5):2056-2066. PubMed ID: 33000227
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Large-scale transcriptome profiles reveal robust 20-signatures metabolic prediction models and novel role of G6PC in clear cell renal cell carcinoma.
    Xu WH; Xu Y; Tian X; Anwaier A; Liu WR; Wang J; Zhu WK; Cao DL; Wang HK; Shi GH; Qu YY; Zhang HL; Ye DW
    J Cell Mol Med; 2020 Aug; 24(16):9012-9027. PubMed ID: 32567187
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FCER1G positively relates to macrophage infiltration in clear cell renal cell carcinoma and contributes to unfavorable prognosis by regulating tumor immunity.
    Dong K; Chen W; Pan X; Wang H; Sun Y; Qian C; Chen W; Wang C; Yang F; Cui X
    BMC Cancer; 2022 Feb; 22(1):140. PubMed ID: 35120484
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CPA4 as a biomarker promotes the proliferation, migration and metastasis of clear cell renal cell carcinoma cells.
    Wang K; Ding Y; Liu Y; Ma M; Wang J; Kou Z; Liu S; Jiang B; Hou S
    J Cell Mol Med; 2024 Apr; 28(7):e18165. PubMed ID: 38494845
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PRMT1 is a novel molecular therapeutic target for clear cell renal cell carcinoma.
    Wang J; Wang C; Xu P; Li X; Lu Y; Jin D; Yin X; Jiang H; Huang J; Xiong H; Ye F; Jin J; Chen Y; Xie Y; Chen Z; Ding H; Zhang H; Liu R; Jiang H; Chen K; Yao Z; Luo C; Huang Y; Zhang Y; Zhang J
    Theranostics; 2021; 11(11):5387-5403. PubMed ID: 33859753
    [No Abstract]   [Full Text] [Related]  

  • 19. Downregulation of
    Wang T; Xie F; Li YH; Liang B
    Future Oncol; 2021 Dec; 17(36):5033-5044. PubMed ID: 34704468
    [TBL] [Abstract][Full Text] [Related]  

  • 20. APOBEC family reshapes the immune microenvironment and therapy sensitivity in clear cell renal cell carcinoma.
    Huang G; Zhan X; Shen L; Lou L; Dai Y; Jiang A; Gao Y; Wang Y; Xie X; Zhang J
    Clin Exp Med; 2024 Sep; 24(1):212. PubMed ID: 39249558
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.